Price Alert

Lyra Therapeutics Inc. (LYRA)

NASDAQ: LYRA · Real-Time Price · USD

7.04

-0.14 (-1.95%)

At close: Sep 04, 2025, 3:59 PM

7.03

-0.14%

After-hours: Sep 04, 2025, 06:35 PM EDT

-1.95% (1D)

Bid	6.9
Market Cap	11.58M
Revenue (ttm)	770K
Net Income (ttm)	-38.84M
EPS (ttm)	-28.99
PE Ratio (ttm)	-0.24
Forward PE	-0.75
Analyst	Hold

Ask	7.39
Volume	5,926
Avg. Volume (20D)	110,733
Open	7.18
Previous Close	7.18
Day's Range	7.01 - 7.18
52-Week Range	3.81 - 37.50
Beta	0.17

About LYRA

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol LYRA

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for LYRA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Lyra Therapeutics Inc. is scheduled to release its earnings on Nov 11, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 months ago

-31.91%

Lyra Therapeutics shares are trading lower after t... Unlock content with Pro Subscription

3 months ago

+310.75%

Lyra Therapeutics shares are trading higher after the company announced its ENLIGHTEN 2 Phase 3 trial of LYR-210 met its primary endpoint.

News

3 weeks ago · zacks.com

Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Beats Revenue Estimates

Lyra Therapeutics, Inc. (LYRA) came out with a quarterly loss of $5.51 per share versus the Zacks Consensus Estimate of a loss of $5.79. This compares to a loss of $14.5 per share a year ago.

2 months ago · seekingalpha.com

Lyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated Catalyst

Lyra Therapeutics has lost >90% of its value since announcing the failed ENLIGHTEN-1 trial, despite the recent announcement of a clearly positive ENLIGHTEN-2. Considering a clearly positive phase 3, s...

2 months ago · zacks.com

Lyra Therapeutics (LYRA) Upgraded to Buy: Here's Why

Lyra Therapeutics (LYRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

3 months ago · zacks.com

Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success

LYRA skyrockets 356% after its lead nasal implant, LYR-210, meets key goals in a pivotal phase III chronic rhinosinusitis study.